Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sameer Bhargava

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Haematologica|June 12, 2025
Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphomaKjersti Lia, Rasmus Rask Kragh Jørgensen, Per Wikman, et al.
Leukemia & Lymphoma|February 28, 2026
Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional surveyKjersti Lia, Renate B Galleberg, Siri Rostoft, et al.
Future Oncology (London, England)|July 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerKamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Haematologica|June 12, 2025
Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphomaKjersti Lia, Rasmus Rask Kragh Jørgensen, Per Wikman, et al.
Leukemia & Lymphoma|February 28, 2026
Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional surveyKjersti Lia, Renate B Galleberg, Siri Rostoft, et al.
Future Oncology (London, England)|July 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerKamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, et al.
Pageof 3